Search Site

Search form

Pipeline

Vertex has a broad and diverse pipeline of potential medicines in development.

VX-809 VX-661 VX-135 VX-509 VX-787

VX-809

VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.  VX-809 is being studied in combination with ivacaftor for people with cystic fibrosis who have the F508del mutation.  Vertex has worldwide rights to develop and commercialize VX-809.


VX-661

VX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.  VX-661 is being studied in combination with ivacaftor for people with cystic fibrosis who have the F508del mutation.  Vertex has worldwide rights to develop and commercialize VX-661.

VX-135

VX-135 is a nucleotide analogue inhibitor of the hepatitis C polymerase that is being evaluated for the treatment of hepatitis C virus infection. Vertex has worldwide rights to develop and commercialize ALS-2200 (VX-135.)

VX-509

VX-509 is an oral medicine being developed by Vertex that is designed to selectively inhibit Janus kinase 3, or JAK3, which is an essential part of the underlying disease mechanisms that cause inflammation, and is being evaluated in diseases such as rheumatoid arthritis. Vertex has worldwide rights to develop and commercialize VX-509.

VX-787

VX-787 is a medicine in development being evaluated for the treatment of influenza A, including recent H1 (pandemic) and H5 (avian) influenza strains. Vertex has worldwide rights to develop and commercialize VX-787.

Last updated: Thursday, October 17, 2013 - 09:58